Search for drugs:
Typing the drug name to query
DEFIBROTIDE SODIUM
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac electrophysiology
- At a dose 2.4 times the maximum recommended dose, DEFITELIO does not prolong the QTc interval to any clinically relevant extent.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
4813
38376774
Odds Ratio = 0.0
Drug Property Information
ATC Code(s):
- B01AX01 - defibrotide sodium
- B01AX - Other antithrombotic agents
- B01A - ANTITHROMBOTIC AGENTS
- B01 - ANTITHROMBOTIC AGENTS
- B - BLOOD AND BLOOD FORMING ORGANS
Active Ingredient:DEFIBROTIDE SODIUM
Active Ingredient UNII:L7CHH2B2J0
Drugbank ID:DB04932
PubChem Compound:N/ADIR Classification
CTD ID:C036901
CAS Number:
Dosage Form(s):injection, solution
Route(s) Of Administrator:intravenous
Daily Dose:
- 1750.0 mg/day B01AX01
Chemical Structure: 
SMILE Code:
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.